Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some of the important genetic events involved in osteosarcoma will be highlighted.
they no longer account for the majority of cases due to an increase in the diversity of primary tumor sites. Craniofacial and axial tumors increase in frequency with age, accounting for 40% of all OS cases after 60 years of age, compared to less than 12% before the age of 24 years [6] . Juxtacortical osteosarcomas that occur along the surface of bones are usually lower grade, although there are some exceptions [9] .
Compliance with Ethics Guidelines
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PREDISPOSING CONDITIONS AND RISK FACTORS FOR OS

Genetics of OS
Phenotypic risk factors for OS are related to physiologic growth and include both a tall height and a high birth weight [10] . The vast majority of cases are the result of sporadic mutations, but loss of tumor suppressor function is commonly identified in OS and represents a critical step in its pathogenesis [11] [12] [13] . Overall, there is no unifying genetic event that leads to the development of OS. In addition to somatic mutations, there are a few well-identified syndromes that predispose to OS, and these are usually discussed to highlight some of the sentinel genetic events that are involved in pathogenesis.
Li-Fraumeni syndrome (LFS) is the most common syndrome predisposing to pediatric sarcomas and involves a germline mutation of the TP53 gene. RecQ helicases are members of a conserved family of proteins that unwind double-stranded DNA prior to replication.
Loss of RecQ helicases is an inheritable risk factor for OS [27, 28] . Germline mutations in genes in the RecQ family give rise to the rare autosomal recessive cancer predisposition disorders (e.g., Bloom's syndrome, Werner's syndrome, and Rothmund-Thomson syndrome), which are all associated with increased incidence of OS [29] .
In addition to genetic alterations due to chromosomal instability and loss of tumor suppressor genes, OS can also have disruptions in major signaling pathways, creating a bone microenvironment that promotes proliferation and metastasis. The TGF-b proteins are part of a superfamily of five isoforms (TGF-b1-5) and the bone morphogenic proteins (BMP1-15) [ primary and metastatic samples [38] . In preclinical studies, OS proliferation was enhanced by IGF-I/II and inhibited when IGF-IR was silenced by monoclonal antibodies, RNA interference, or microRNA [39, 40] .
Increased IGF-1 expression leads to more aggressive phenotypes in vitro and is a negative prognosticator when found in primary tumors [36, 37] . mTOR, a downstream target in the IGF-I/II pathway, is an attractive target in many cancers, and recent efforts have attempted to target this area in OS [41] . 
Staging
Staging is important for detecting metastasis, establishing prognosis, and determining appropriate medical therapy and surgery [53, 63, 66] . Since over 75% of metastases involve the lungs, all patients with bone sarcoma should receive a CT scan of the chest [67, 68] . At presentation, 20% of patients have metastatic disease detectable with current CT imaging. However, the majority of metastatic disease is microscopic, and it is estimated that another 60% of patients have micrometastatic disease [69] [70] [71] . A bone scan or positron emission tomography (PET) scan is recommended to detect metastatic bone and (Fig. 4) . Bone scan is more cost-effective and superior to PET for bony disease, but PET allows for better detection in soft tissue, and includes the chest and abdomen. Both are effective scanning techniques; the choice made usually varies by institution. An additional advantage of PET is that it may be able to identify tumors with higher metabolic activity and, therefore, higher-grade malignancies [72, 73] . Finally, if not already available, an MRI of the entire bone involved is important to rule out any skip metastases, which must be addressed with primary resection and predict a poor survival [74] .
The two staging systems currently employed for staging OS are the Enneking system and the AJCC (Tables 1, 2 ). Enneking was the first to organize bone sarcoma into a comprehensive staging system, and the AJCC later used these principles to develop its own staging system with nomenclature similar to that used for other cancers. Both use histological grade and the presence/absence of metastases and differ in their evaluation of the size of the primary tumor. The Enneking system makes a distinction between whether the mass is intracompartmental or has become extracompartmental, while the AJCC system uses tumor size (\8 or[8 cm) to determine a T1 from a T2 tumor. Despite these differences, most tumors will be a similar stage in both systems, as the major driver of prognosis is the b Fig. 4 X-ray (a) and MRI (b) of the distal femur of a 13-year-old girl, showing a large solitary lesion. However, staging with bone scan (c) and MRI (d) revealed additional skip metastasis in her ipsilateral femur diaphysis and peritrochanteric area that was not detected with initial imaging. The presence of the skip metastases changed the surgical plan from a distal femur resection to an entire femur resection and reconstruction (e) presence of metastases, which both systems define similarly [75] .
Treatment
Prior to the advent of chemotherapy, OS was almost a universally fatal disease. Patients with metastasis at diagnosis would typically survive only months, and those with localized disease would soon develop metastatic spread, despite radical and disabling surgical procedures. In the 1970s, Jaffe published the first significant success of chemotherapy, showing that methotrexate was a useful agent to manage metastases in advanced disease [76] . As new cytotoxic agents were discovered, the use of chemotherapy blossomed, but the practice remained controversial until a landmark study in 1985 which showed an increase in 6-year survival from 11 to 61% with the addition of multi-agent chemotherapy [69] . A study performed during the same time period at Memorial Sloan Kettering found similar increases in survival with chemotherapy that was given before surgery (neoadjuvant), showing that it was safe to delay surgery for treatment [77] . The authors preferred neoadjuvant chemotherapy because it allowed more time to fabricate endoprosthetic devices, decreased tumor size, and permitted an analysis of the surgical specimen for its response to chemotherapy [66] .
Chemotherapy
Today, most OS patients receive neoadjuvant chemotherapy, followed by surgical resection of all detectable disease and a regimen of adjuvant chemotherapy postoperatively [78] . The current regimen of methotrexate, adriamycin, and Radiation treatment is rarely included as an adjuvant, but has been used in unresectable cases [89] [90] [91] . All tumors should be removed with a wide margin to prevent residual disease; the adequacy of this margin is critical in preventing recurrences [92] . Recurrent disease is closely linked to a poor prognosis and the risk of metastatic disease. Following resection, pathological specimens are examined to see the effect that chemotherapy has had on the tumor. A necrosis rate of C90% is considered a ''good response,'' and these patients will have a better prognosis than those with less than 90% necrosis.
Besides found that 42% of patients with endoprosthetic reconstruction required revision or amputation within 10 years, with 51% of these revisions being due to mechanical failure and 33% due to infection [103] . Given a long enough lifespan, most survivors of OS with endoprosthetic reconstruction will have to undergo one or more revision surgeries [104] .
Bulk allograft reconstruction involves matching the resected specimen with a donor graft of comparable size and shape. Successful outcome is contingent on a biological union between the host and implanted bone; rigid fixation is paramount for this process to occur.
Over time, these implants slowly undergo variable rates of osseous and vascular integration by the body and have a theoretical advantage of being a permanent replacement for the resected bone [105] . Other advantages include higher rates of soft-tissue integration and customizability for nonstandard resections.
Unfortunately, failure rates can be as high as 17-20% due to infection, nonunion, or implant fracture. Additionally, union rates are decreased by radiotherapy, chemotherapy, and poor nutritional states, one or more of which is usually present in patients with OS. The risk of failure is highest in the first 3 years but plateaus thereafter. Approximately 75% of patients with a graft present for over 5 years report good or better outcomes as far out as 20 years after surgery [105] .
When used for reconstructing joint surfaces, osteoarticular allografts develop subchondral collapse, with the resulting arthritis quickly leading to early failure. However, they can be combined with manufactured joint implants, resulting in an allograft-prosthetic composite. The outcome is an implant with the advantages (and disadvantages) of both an allograft and an endoprosthesis. The allograft side allows for a stronger and more complete reconstruction of the periarticular soft-tissue envelope and incorporates into the patient's host bone, while the prosthetic side creates a stable and predictable joint articulation. These implants represent a high degree of complexity for the surgeon, but have been shown by several centers to provide a stable reconstruction with similar failure rates to other methods [106, 107] .
Most OS cases occur in younger patients, many of which have active growth plates at the time of diagnosis. Since most of these tumors originate in the metaphysis and expand circumferentially, the physis is often at risk.
When the physis must be sacrificed along with the tumor mass, reconstruction must plan to resolve or prevent significant limb length discrepancy resulting from growth. In lower extremities, this is usually agreed to be a limb length discrepancy of greater than 2 cm at maturity, but is less defined in the upper extremity. A variety of options exist, and the appropriate choice is often a subject of controversy. Reconstruction strategies include leaving the operative extremity longer than the contralateral side to allow growth, slowing or halting the growth of the nonoperative limb, replacing the defect with an implant that can be expanded as the child grows, or choosing a functional amputation, such as Van Ness rotationplasty (Fig. 6) .
In our institution, we have found success with a physeal sparing resection with allograft reconstruction when possible (Fig. 7) . This technique has been recently reported in a series of 35 Argentinean patients with 95% survival of the limb at 5 and 10 years [108] . When the physis cannot be preserved, we prefer modulated growth for defects of less than 3 cm and an expandable prosthesis for larger defects. Several expandable implants exist on the market. Some require minimal surgery for mechanical expansion, while others rely on an electromagnet for noninvasive lengthening. The noninvasive implants have the advantage of avoiding further surgery, but the first generation has had an intolerable failure rate [109, 110] .
Second-generation noninvasive implants have only been available for a short time, but may be more stable. Most expandable prostheses will eventually have to undergo revision, given the age and activity level of their patients.
Rotationplasty remains a useful and lasting option in patients with distal femur OS, especially for patients who desire high-demand activity, but few patients and their parents are comfortable with this type of amputation [111] .
OS in axial locations is rare, but often presents unique challenges. Pelvis OS accounts for only about 8% of all cases, but these tumors tend to be larger, more biologically active, and have metastatic disease more often compared to extremity OS [112, 113] . Resection is still necessary for cure, but is more complicated given the three-dimensional anatomy of the bony pelvis and surrounding vital structures.
Reconstruction is also more difficult and should only be attempted in certain cases, as many reconstructions only increase the complication rate without improving postoperative function [114, 115] . In addition to surgery, radiotherapy can be used for added local control and may improve overall survival [116] . OS of the spine is rare as well but, when present, usually occurs in the vertebral body and requires en-bloc b Fig. 5 A 22-year-old male with an osteosarcoma of the proximal tibia. XR images (a) show an aggressive lesion of the proximal tibia with abundant osseous matrix. Resection of the tumor mass was performed with care taken to spare the neurovascular bundle (b), and then the defect was reconstructed with a proximal tibia endoprosthesis (c) and a medial gastrocnemius muscle flap for soft-tissue coverage (d). Resected tumor specimen (e, f) and gross pathology examination resection for cure [117] . OS metastases, when present, should be removed in close chronology to the main tumor. Although lung metastasis predicts a poorer prognosis, resection of metastatic disease can still lead to remission in some cases and has been shown to improve survival [118, 119] . Advanced adult age is associated with increases in both higher-grade tumors and axial tumors, along with decreased response to and toleration of chemotherapy. Subsequently, older adults have a poorer prognosis [123] . Recurrent disease, either local or distant, decreases average 5-year survival to 20%, but can be as high as 45% for relapses greater than 2 years out that can be surgically resected. Lower-grade osteosarcomas, including parosteal and Fig. 7 17-year-old male with periosteal osteosarcoma. MRI images (a, b) show the cortically based tumor is located in the metaphysis with some invasion of the marrow and a soft-tissue mass. A polyhedral, metaphysis-sparing bone cut was planned with navigation software (c), and intraoperative guidance was used to assist with the bone cuts according to the preoperative plan (d).
A matching allograft was used to fill the defect and fixed to the patient's remaining bone (e). Two-year follow-up shows robust union at the junction sites (f) periosteal sarcomas, have a much better prognosis than the high-grade conventional type. The 5-year survival of periosteal sarcoma is around 83%, and parosteal sarcoma has a reported 5-year survival of 91%. This is primarily due to the low rate of metastasis.
New Therapies
A number of preclinical and clinical agents are currently being investigated for OS. One area of significant research involves using specific agents to target known processes important in OS pathogenesis. One attractive target is the mTOR pathway, a downstream pathway of IGF-1 that stimulates proliferation, survival, and angiogenesis. Sirolimus, an mTOR inhibitor, was found to inhibit metastasis and OS xenograft growth in mice [124, 125] . Everolimus, an oral mTOR inhibitor, also showed activity against human and mice OS cells, an effect that was enhanced by combination with zoledronic acid [126] . A recent phase I trial has shown that oral everolimus is safe in pediatric populations [127] , and a phase II study is currently ongoing in refractory OS [128] . Disruption of angiogenesis is another strategy, and several targeted agents have been tested in OS. Pazopanib is an inhibitor of VEGFR, PDGFR, and c-kit that has shown some efficacy in metastatic OS [129] . The drug is well tolerated in children and currently under investigation in a phase II clinical trial among OS patients with lung metastases. Sorafenib is an oral anti-angiogenic agent with activity against VEGFR-2 and PDFGR-B that has shown good activity as a second-or third-line agent in refractory OS [130] . Surprisingly, a recent clinical study failed to show efficacy when sorafenib was combined with everolimus in inoperable high-grade progressive OS patients [131] .
Immune modulation is another area of increased OS research. As discussed earlier, 
